Effect of artemether on pentobarbitone sleep and electrical activity in rats.
Artemether (AM), a highly effective treatment for multidrug-resistant malaria and a component of artemisinin combination therapy, has been associated with some neurotoxicity following repeated high doses. This study was aimed at investigating the effect of AM on pentobarbitone sleep and electrical activities in rats. Wistar rats received AM i.p. at 3 dose levels: 1.5, 7.5, and 15 mg/kg, whereas control rats received 0.2 mL of the vehicle (3% v/v Tween 80). AM administered 20 min before pentobarbitone had no significant effect on the onset and duration of sleep. However, after a 7-day pretreatment, AM dose-dependently prolonged pentobarbitone sleep, as did chloramphenicol. Electroencephalogram and electromyogram recordings 20 min after pretreatment showed that AM (15 mg/kg) exhibited inhibitory activity similar to chlorpromazine as opposed to the excitatory effect of amphetamine. When pretreated for 7 days, rats receiving 1.5 mg/kg AM also showed inhibitory activity of the cortical centres, whereas desynchronization of the optic tectum and reticular formation was observed in rats pretreated with 7.5 and 15 mg/kg AM. The present data suggest that although the therapeutic equivalent dose of 1.5 mg/kg AM had no appreciable effects on pentobarbitone sleep but caused reduced electrical activity in rats, higher doses have more profound effects on both indices.
Ejiofor
Janet I
JI
Department of Pharmacology and Clinical Pharmacy, Ahmadu Bello University, PMB 1045, Zaria, 810271, Kaduna State, Nigeria. akanwajane@yahoo.com
Kwanashie
Helen O
HO
Anuka
Joseph A
JA
D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage / Q000494:pharmacology; D014150:Antipsychotic Agents / Q000494:pharmacology; D000077549:Artemether; D037621:Artemisinins / Q000008:administration & dosage / Q000494:pharmacology*; D000697:Central Nervous System Stimulants / Q000494:pharmacology; D002701:Chloramphenicol / Q000031:analogs & derivatives / Q000494:pharmacology; D002746:Chlorpromazine / Q000494:pharmacology; D003344:Cortical Synchronization / Q000379:methods; D004305:Dose-Response Relationship, Drug; D004576:Electromyography / Q000379:methods; D005260:Female; D006993:Hypnotics and Sedatives / Q000494:pharmacology; D007274:Injections, Intraperitoneal; D008297:Male; D010424:Pentobarbital / Q000494:pharmacology*; D010634:Phenobarbital / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012154:Reticular Formation / Q000187:drug effects / Q000502:physiology; D012890:Sleep / Q000187:drug effects* / Q000502:physiology; D013477:Superior Colliculi / Q000187:drug effects / Q000502:physiology; D013997:Time Factors